Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SIGILON THERAPEUTICS, INC.

(SGTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sigilon Therapeutics : UK Regulator Accepts Sigilon's Clinical Trial Application for Lysosomal Disease Therapeutic

09/09/2021 | 08:30am EDT


ę MT Newswires 2021
All news about SIGILON THERAPEUTICS, INC.
09/09SIGILON THERAPEUTICS : UK Regulator Accepts Sigilon's Clinical Trial Application for Lysos..
MT
09/09Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for S..
GL
09/09Sigilon Therapeutics, Inc. Announces Acceptance of Clinical Trial Application in the UK..
CI
09/02SIGILON THERAPEUTICS : to Participate in Two Upcoming Healthcare Investor Conferences
AQ
08/10SIGILON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/10SIGILON THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Highligh..
PU
08/10SIGILON THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD ..
AQ
08/10SIGILON THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Highligh..
AQ
08/10Sigilon Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Se..
CI
08/10Sigilon Therapeutics, Inc. Announces Resignation of Deya Corzo as Chief Medical Officer
CI
More news
Analyst Recommendations on SIGILON THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 11,7 M - -
Net income 2021 -78,0 M - -
Net cash 2021 117 M - -
P/E ratio 2021 -2,24x
Yield 2021 -
Capitalization 178 M 178 M -
EV / Sales 2021 5,23x
EV / Sales 2022 -3,89x
Nbr of Employees 99
Free-Float 78,1%
Chart SIGILON THERAPEUTICS, INC.
Duration : Period :
Sigilon Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIGILON THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,55 $
Average target price 20,75 $
Spread / Average Target 274%
EPS Revisions
Managers and Directors
RogÚrio Vivaldi Coelho President, Chief Executive Officer & Director
Josias Pontes Vice President & Head-Finance
Douglas G. Cole Chairman
Deya Corzo Chief Medical Officer
Martha Rook Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
SIGILON THERAPEUTICS, INC.-88.44%178
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414